Life Sciences
Top stories summarized by our editors
9/18/2018

Laila Ali is the spokeswoman of a campaign for Astellas Pharma's bladder control drug Myrbetriq in a campaign that will run during ABC's "Dancing with the Stars." This is the second year Astellas has promoted the drug during the show.

Full Story:
FiercePharma
More Summaries:
Laila Ali, DWTS, Astellas, ABC, Astellas
9/18/2018

Interpublic Group CEO Michael Roth has reportedly discussed who could succeed him when he retires, and possible candidates are Philippe Krakowsky, IPG chief strategy and talent officer, and Harris Diamond, CEO and chairman of McCann Worldgroup. Roth, who is 72, has led the agency since 2005.

Full Story:
MM&M
9/17/2018

The USDA and the FDA will partner to hear public discussion about the possible hazards related to lab-grown meat products and techniques to control such hazards. Also included in the discussion will be labeling and naming issues, such as using the terms "clean meat," "lab-grown," "cell-based" or "plant-based" for lab-grown products.

Full Story:
Food Safety News
More Summaries:
FDA, USDA
9/17/2018

The NIH has launched the Cure Sickle Cell Initiative, a program that will create a national repository for data on the disease and focus on developing gene therapies for patients with sickle cell disease, with Dana-Farber Cancer Institute's Dr. Edward Benz Jr. as its executive director. Patient engagement will be key to the initiative, with patients working together with researchers in search of effective therapies for SCD and in the development and recruitment of participants for clinical trials.

Full Story:
Rare Disease Report
9/17/2018

FDA Commissioner Scott Gottlieb called for new funding mechanisms to support the battle against antimicrobial resistance, while also disclosing the agency's 2019 strategic plan that focuses on AMR. Gottlieb spoke of four crucial areas to address, including the development of products and surveillance tools for antimicrobial use and resistance, promotion of antimicrobial stewardship and support for research initiatives to discover alternative treatment approaches.

Full Story:
BioCentury
More Summaries:
Commissioner Scott Gottlieb, FDA
9/17/2018

An FDA fast-track designation was granted to ArQule's miransertib, being developed as a treatment for patients with PIK3CA-related overgrowth spectrum. ArQule has an ongoing Phase I/II trial for the indication.

Full Story:
eMPR
More Summaries:
FDA, ArQule
9/17/2018

Draft guidance outlining the process of determining the eligibility of certain devices for review under the 510(k) Third Party Review Program has been released by the FDA, along with a plan to reduce the number of 510(k) submissions the agency has to review after they have been reviewed by a third party. AdvaMed is still looking into the plan, although it is "pleased FDA has released the guidance," says Mark Brager, vice president of communications.

Full Story:
MedTech Dive
9/17/2018

Biotronik has obtained approval from the FDA for its PK Papyrus covered coronary stent system for the treatment of acute coronary artery perforations via the agency's humanitarian device exemption pathway. The 5-French compatible, balloon-expandable coronary stent system, which comes in 17 sizes, is not indicated for use in candidates who are ineligible for standard percutaneous coronary intervention procedures or those with a known hypersensitivity or allergy to any compound of the stent system.

More Summaries:
FDA, Biotronik
9/17/2018

HHS Secretary Alex Azar expressed complete support over the FDA's proposed crackdown on e-cigarettes, which includes an order to five e-cigarette brands to submit plans on mitigating teen e-cigarette use within 60 days.

Full Story:
CNBC
More Summaries:
HHS, FDA, Alex Azar
9/17/2018

ViiV Healthcare has submitted to the European Medicines Agency a marketing authorization application for its single-tablet combo drug of Tivicay, or dolutegravir, and Epivir, or lamivudine, to treat patients with HIV-1 infection. ViiV plans to file a new drug application with the US FDA for the regimen in October.

Full Story:
PharmaBiz (India)